Kazia raises A$4.0 M to progress R&D programs
Singapore, Oct. 29 -- Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, on 28 October 2019, announced that the completion of a placement of ten million new fully paid ordinary shares in the Company to institutional, professional, and sophisticated investors in Australia and internationally, at a price of A$0.40 per New Share (Institutional Placement). The Institutional Placement will raise A$4.0 million (exclusive of costs).
Key Points
Oversubscribed Institutional Placement led by multiple high-quality institutional investors in Australia and Asia
Company has capitalised on recent appreciation in share price, driven by emerging data from broad-based clinical trial programs, and has substantially strength...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.